Regulus Therapeutics Inc Forecasted to Post FY2022 Earnings of $0.47 Per Share (RGLS)

Regulus Therapeutics Inc (NASDAQ:RGLS) – Investment analysts at Wedbush issued their FY2022 EPS estimates for Regulus Therapeutics in a research note issued on Thursday. Wedbush analyst L. Moussatos expects that the biopharmaceutical company will post earnings of $0.47 per share for the year. Wedbush currently has a “Outperform” rating and a $4.00 target price on the stock.

Other equities research analysts have also issued research reports about the stock. Zacks Investment Research upgraded shares of Regulus Therapeutics from a “hold” rating to a “buy” rating and set a $1.50 price objective for the company in a research note on Wednesday, January 24th. Leerink Swann began coverage on shares of Regulus Therapeutics in a research note on Friday, January 5th. They issued an “outperform” rating and a $2.00 price objective for the company. Needham & Company LLC reiterated a “hold” rating on shares of Regulus Therapeutics in a research note on Tuesday, November 14th. Finally, Chardan Capital reiterated a “neutral” rating on shares of Regulus Therapeutics in a research note on Tuesday, January 16th. One analyst has rated the stock with a sell rating, five have given a hold rating and three have assigned a buy rating to the company’s stock. The company presently has an average rating of “Hold” and an average price target of $2.50.

Shares of Regulus Therapeutics (RGLS) opened at $1.13 on Monday. The company has a debt-to-equity ratio of 0.41, a current ratio of 6.77 and a quick ratio of 6.77. The company has a market cap of $115.39, a PE ratio of -0.84 and a beta of 1.72. Regulus Therapeutics has a one year low of $0.79 and a one year high of $1.95.

Institutional investors have recently added to or reduced their stakes in the company. NEA Management Company LLC bought a new position in shares of Regulus Therapeutics during the 3rd quarter valued at approximately $13,737,000. Victory Capital Management Inc. bought a new position in shares of Regulus Therapeutics during the 3rd quarter valued at approximately $347,000. Goldman Sachs Group Inc. grew its position in shares of Regulus Therapeutics by 189.1% during the 2nd quarter. Goldman Sachs Group Inc. now owns 368,285 shares of the biopharmaceutical company’s stock valued at $363,000 after acquiring an additional 240,890 shares during the period. Candriam Luxembourg S.C.A. bought a new position in shares of Regulus Therapeutics during the 3rd quarter valued at approximately $750,000. Finally, South Dakota Investment Council grew its position in shares of Regulus Therapeutics by 37.1% during the 3rd quarter. South Dakota Investment Council now owns 1,820,027 shares of the biopharmaceutical company’s stock valued at $2,275,000 after acquiring an additional 492,969 shares during the period. 59.32% of the stock is owned by hedge funds and other institutional investors.

TRADEMARK VIOLATION WARNING: “Regulus Therapeutics Inc Forecasted to Post FY2022 Earnings of $0.47 Per Share (RGLS)” was originally published by American Banking News and is the property of of American Banking News. If you are reading this piece of content on another publication, it was illegally copied and republished in violation of US and international copyright and trademark law. The legal version of this piece of content can be viewed at https://www.americanbankingnews.com/2018/02/12/regulus-therapeutics-inc-forecasted-to-post-fy2022-earnings-of-0-47-per-share-rgls.html.

About Regulus Therapeutics

Regulus Therapeutics Inc is a biopharmaceutical company focused on discovering and developing drugs that target microRNAs to treat a range of diseases. The Company uses its microRNA product platform to develop chemically modified, single-stranded oligonucleotides that the Company calls anti-miRs to modulate microRNAs and return diseased cells to their healthy state.

Earnings History and Estimates for Regulus Therapeutics (NASDAQ:RGLS)

Receive News & Ratings for Regulus Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regulus Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply